CML Clinical Trial
Official title:
A Phase IV Study for Nilotinib in Patients With Imatinib-resistant or Intolerant Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML) in Chronic or Accelerated Phase.
The purpose of this study is to evaluate efficacy and safety of nilotinib in patients with Imatinib resistant or intolerant CML-CP or AC. Efficacy evaluation will be made by Complete cytogenetic response rate(CCyR) at 12 months after nilotinib administration.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00333190 -
CD8+ T Cell Depletion for GVHD Prophylaxis After Peripheral Blood Stem Cell Transplantation
|
N/A | |
| Terminated |
NCT01131325 -
Study of Nilotinib in Ph+ CML-CP Patients With Low Imatinib Trough Plasma Concentrations
|
Phase 4 | |
| Active, not recruiting |
NCT03578367 -
Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
|
Phase 2 | |
| Completed |
NCT03747679 -
Palatability (Taste) of Oral Formulations of Bosutinib
|
Phase 1 | |
| Completed |
NCT01019317 -
Fludarabine and Cytarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)
|
Phase 2 | |
| Recruiting |
NCT06131801 -
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
|
||
| Not yet recruiting |
NCT06423911 -
A Phase 3 Registrational Study of Olverembatinib (HQP1351) in Patients With CML
|
Phase 3 | |
| Completed |
NCT03880617 -
Distress, Medication Adherence and Care Needs in Patients With CML and GIST Receiving Oral Targeted Therapy
|
||
| Completed |
NCT00858572 -
STA-9090 for Treatment of AML, CML, MDS and Myeloproliferative Disorders
|
Phase 1 | |
| Completed |
NCT00684008 -
Safety Study of IL-7 in Recipients of a Hemopoietic Stem Cell Transplant Peripheral Blood Stem Cell Transplant
|
Phase 1 | |
| Completed |
NCT00013533 -
Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies
|
Early Phase 1 | |
| Not yet recruiting |
NCT06047886 -
CD34 Selection Using the Automated CliniMACS Prodigy
|
Phase 1 | |
| Recruiting |
NCT05823571 -
Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients
|
Phase 1 | |
| Completed |
NCT00780104 -
Sirolimus in Combination With MEC in High Risk Myeloid Leukemias
|
Phase 1 | |
| Recruiting |
NCT06211166 -
Assessment of Measurable Residual Disease in Allo-HSCT Using Digital Polymerase Chain Reaction
|
||
| Recruiting |
NCT01762969 -
Treatment Modification Based on Early Assessment of CML Patients
|
Phase 2 | |
| Completed |
NCT00891592 -
Umbilical Cord Blood Transplant for Hematological Malignancies
|
Phase 1 | |
| Terminated |
NCT00776373 -
Rapamycin in With High-Dose Etoposide and Cytarabine in Relapsed/Refractory Aggressive Lymphoid Malignancies
|
Phase 1/Phase 2 | |
| Completed |
NCT00511537 -
Unrelated Stem Cell Transplantation for Adults With Hematopoietic Disorders
|
N/A | |
| Recruiting |
NCT05152537 -
FLOR3 Gene Polymorphism in Predicting Outcomes of Tyrosine Kinase Inhibitor（TKI）Stopping in Chronic Myeloid Leukemia
|